The DOI matches its Crossref record.
Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy
Abstract
The aim of our study was to evaluate whether inhibition of ACE (lisinopril 10–20 mg/day) can reduce the rate of decline in kidney function more than reducing blood pressure with conventional antihypertensive treatment (atenolol 50–100 mg/day), usually in combination with a diuretic. We performed a prospective, randomized, parallel study for 42 months, double blind for the first 12 months and single blind thereafter. Forty-three (21 lisinopril and 22 atenolol) hypertensive NIDDM patients with diabetic nephropathy were enrolled. Data from 36 patients (17 lisinopril and 19 atenolol, 60 ± 7 years of age, 27 men) who completed at least 12 months of the study period are presented. At baseline, the two groups were comparable: glomerular filtration rate (51Cr-EDTA plasma clearance) was 75 ± 6 and 74 ± 8 ml · min−1 · 1.73 m−2, mean 24-h ambulatory blood pressure (A&D TM2420) was 110 ± 3 and 114 ± 2 mmHg, and 24-h urinary albumin excretion rate was 961 (range 331–5,727) and 1,578 (476–5,806) mg/24 h in the lisinopril and atenolol groups, respectively. The mean follow-up time was similar, 37 and 35 months in the lisinopril and atenolol groups, respectively. Mean ambulatory blood pressure was equally reduced in the two groups, 12 ± 2 and 10 ± 2 mmHg in the lisinopril and atenolol groups, respectively. Glomerular filtration rate declined in a biphasic manner with a faster initial (0 to 6 months) change of 1.25 ± 0.49 and 0.81 ± 0.29 ml · min−1 · month−1 followed by a slower sustained decline (6 to 42 months) of 0.59 ± 0.10 and 0.54 ± 0.13 ml · min−1 · month−1 in the lisinopril and atenolol groups, respectively. No significant differences were observed in either initial or sustained decline in glomerular filtration rate between the two groups. Urinary albumin excretion was reduced (% reduction of baseline) more in the lisinopril than in the atenolol group, at 55 (95% CI 29–72) and 15% (−13 to 34), respectively (P = 0.01). In conclusion, the relentless decline in kidney function characteristically found in hypertensive NIDDM patients with diabetic nephropathy can be reduced equally effectively by two antihypertensive treatments, the β-blocker atenolol and the ACE inhibitor lisinopril.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationCheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Nephropathy in Patients with Type 2 Diabetes Mellitus
Ritz, E., & Orth, S. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411506 · Cited by 757
(2000) · PubMed · Cited by 691
Nephropathy in Patients with Type 2 Diabetes
Remuzzi, G., Schieppati, A., & Ruggenenti, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011773 · Cited by 587
Metadata
- Authors
- Nielsen, F. S., Rossing, P., Gall, M.-A., Skøtt, P., Smidt, U. M., & Parving, H.-H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-07-01
- Volume
- 46
- Issue
- 7
- Pages
- 1182-1188
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1966972471
- Cited by
- 183
- References
- 0
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. https://app.cochat.ai/papers/10.2337/diab.46.7.1182
- The paper
- Nielsen, F. S., Rossing, P., Gall, M.-A., Skøtt, P., Smidt, U. M., & Parving, H.-H. (1997). Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. Diabetes. https://doi.org/10.2337/diab.46.7.1182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.